BCRX
Income statement / Annual
Last year (2024), BioCryst Pharmaceuticals, Inc.'s total revenue was $450.71 M,
an increase of 36.00% from the previous year.
In 2024, BioCryst Pharmaceuticals, Inc.'s net income was -$88.88 M.
See BioCryst Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$450.71 M |
$331.41 M |
$270.83 M |
$157.17 M |
$17.81 M |
$48.84 M |
$20.65 M |
$25.19 M |
$26.35 M |
$48.26 M |
| Cost of Revenue |
$12.27 M
|
$4.66 M
|
$6.59 M
|
$7.26 M
|
$1.68 M
|
$4.10 M
|
$471,000.00
|
$1.70 M
|
$2.70 M
|
$1.90 M
|
| Gross Profit |
$438.44 M
|
$326.75 M
|
$264.23 M
|
$149.91 M
|
$16.14 M
|
$44.73 M
|
$20.18 M
|
$23.48 M
|
$23.65 M
|
$46.36 M
|
| Gross Profit Ratio |
0.97
|
0.99
|
0.98
|
0.95
|
0.91
|
0.92
|
0.98
|
0.93
|
0.9
|
0.96
|
| Research and Development Expenses |
$174.64 M
|
$216.57 M
|
$253.30 M
|
$208.81 M
|
$122.96 M
|
$107.07 M
|
$84.89 M
|
$66.96 M
|
$61.01 M
|
$72.76 M
|
| General & Administrative Expenses |
$0.00
|
$199.14 M
|
$144.48 M
|
$113.11 M
|
$61.36 M
|
$0.00
|
$29.51 M
|
$13.93 M
|
$11.25 M
|
$13.05 M
|
| Selling & Marketing Expenses |
$0.00
|
$14.40 M
|
$14.89 M
|
$5.71 M
|
$6.57 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$266.13 M
|
$213.89 M
|
$159.37 M
|
$118.82 M
|
$67.93 M
|
$37.12 M
|
$29.51 M
|
$13.93 M
|
$11.25 M
|
$13.05 M
|
| Other Expenses |
$216,000.00
|
$0.00
|
$253.27 M
|
$202.92 M
|
$111.96 M
|
$82.44 M
|
$70.81 M
|
$54.38 M
|
$47.01 M
|
$33.71 M
|
| Operating Expenses |
$440.99 M
|
$430.46 M
|
$412.67 M
|
$327.63 M
|
$190.89 M
|
$144.19 M
|
$114.40 M
|
$80.90 M
|
$72.26 M
|
$85.81 M
|
| Cost And Expenses |
$453.26 M
|
$435.12 M
|
$419.26 M
|
$334.89 M
|
$192.57 M
|
$148.29 M
|
$114.87 M
|
$82.60 M
|
$74.96 M
|
$87.70 M
|
| Interest Income |
$14.75 M
|
$15.78 M
|
$5.13 M
|
$62,000.00
|
$9.42 M
|
$1.93 M
|
$2.25 M
|
$1.02 M
|
$793,000.00
|
$535,000.00
|
| Interest Expense |
$98.52 M
|
$108.24 M
|
$99.09 M
|
$59.29 M
|
$14.50 M
|
$11.89 M
|
$9.18 M
|
$8.57 M
|
$6.49 M
|
$5.20 M
|
| Depreciation & Amortization |
$1.25 M
|
$1.66 M
|
$1.44 M
|
$777,000.00
|
$748,000.00
|
$724,000.00
|
$770,000.00
|
$704,000.00
|
$483,000.00
|
$180,000.00
|
| EBITDA |
$12.81 M |
-$116.34 M |
-$143.85 M |
-$121.74 M |
-$167.57 M |
-$96.28 M |
-$90.37 M |
-$56.51 M |
-$48.17 M |
-$37.64 M |
| EBITDA Ratio |
0.03
|
-0.35
|
-0.53
|
-1.13
|
-9.28
|
-2
|
-4.45
|
-2.24
|
-1.81
|
-0.81
|
| Operating Income Ratio |
-0.01
|
-0.31
|
-0.55
|
-1.13
|
-9.81
|
-2.04
|
-4.56
|
-2.28
|
-1.84
|
-0.82
|
| Total Other Income/Expenses Net |
-$84.41 M
|
-$122.52 M
|
-$95.95 M
|
-$4.09 M
|
-$8.06 M
|
-$9.44 M
|
-$7.03 M
|
-$8.37 M
|
-$6.54 M
|
-$3.58 M
|
| Income Before Tax |
-$86.95 M
|
-$226.23 M
|
-$244.38 M
|
-$181.81 M
|
-$182.81 M
|
-$108.90 M
|
-$101.25 M
|
-$65.78 M
|
-$55.14 M
|
-$43.02 M
|
| Income Before Tax Ratio |
-0.19
|
-0.68
|
-0.9
|
-1.16
|
-10.26
|
-2.23
|
-4.9
|
-2.61
|
-2.09
|
-0.89
|
| Income Tax Expense |
$1.93 M
|
$310,000.00
|
$2.73 M
|
$2.25 M
|
$13.75 M
|
$11.17 M
|
$2.14 M
|
$7.86 M
|
$6.00 M
|
$5.02 M
|
| Net Income |
-$88.88 M
|
-$226.54 M
|
-$247.12 M
|
-$184.06 M
|
-$196.57 M
|
-$120.07 M
|
-$101.25 M
|
-$65.78 M
|
-$55.14 M
|
-$43.02 M
|
| Net Income Ratio |
-0.2
|
-0.68
|
-0.91
|
-1.17
|
-11.04
|
-2.46
|
-4.9
|
-2.61
|
-2.09
|
-0.89
|
| EPS |
-0.43 |
-1.18 |
-1.33 |
-1.03 |
-1.18 |
-1.04 |
-0.98 |
-0.78 |
-0.75 |
-0.59 |
| EPS Diluted |
-0.43 |
-1.18 |
-1.33 |
-1.03 |
-1.18 |
-1.04 |
-0.98 |
-0.78 |
-0.75 |
-0.59 |
| Weighted Average Shares Out |
$206.70 M
|
$192.20 M
|
$185.91 M
|
$179.12 M
|
$167.27 M
|
$115.60 M
|
$103.19 M
|
$84.45 M
|
$73.70 M
|
$72.90 M
|
| Weighted Average Shares Out Diluted |
$206.70 M
|
$192.20 M
|
$185.91 M
|
$179.12 M
|
$167.27 M
|
$115.60 M
|
$103.19 M
|
$84.45 M
|
$73.70 M
|
$72.90 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
